Period:

End of Day 1 Minute 5 Minute 10 Minute 15 Minute 30 Minute Hourly Weekly Monthly Yearly

NASDAQ, IMGN - Immunogen Inc

In this Annual Report on Form 10-K, ImmunoGen, Inc. (ImmunoGen, Inc., together  with its subsidiaries, is referred to in this document as we, us, ImmunoGen, or  the Company), incorporates by reference certain information from parts of other  documents filed with the Securities and Exchange Commission. The Securities and  Exchange Commission allows us to disclose important information by referring to  it in that manner. Please refer to all such information when reading this Annual  Report on Form 10-K. All information is as of June 30, 2006 unless otherwise  indicated. For a description of the risk factors affecting or applicable to our  business, see ?Risk Factors,? below.  The Company  We develop novel, targeted therapeutics for the treatment of cancer using our  expertise in cancer biology, monoclonal antibodies (antibodies), and small  molecule cell-killing (cytotoxic) agents.  ...

Read SEC Filing on NASDAQ.com »

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	N/A
PEG Ratio:	N/A
EPS:	N/A
DivYield:	N/A
PtB:	N/A
PtS:	5.58
EBITDA:	N/A
Shares:	89.60M
Market Cap:	2.80B
52wk range:	3.61 - 31.24